Workflow-embedded automation improves hepatitis B screening and safety in b/tsDMARD users
Meng Hsuan Kuo·Ning‐Sheng Lai·Chun‐Yao Huang·Kuo-Chih Tseng·Ming-Chi Lu·Chien‐Hsueh Tung·N Chen·Kuang-Yung Huang·Chih‐Wei Tseng
Despite guideline-mandated universal screening, adherence to hepatitis B virus (HBV) testing before the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) remains suboptimal, placing patients at risk for HBV reactivation (HBVr). We retrospectively studied 1,909 adults starting b/tsDMARD therapy from 2004 to 2024, comparing three stages: baseline (2004–2016), education (2017–2020), and work-flow-integrated (2021–2024). In the last stage, a workflow-e